Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

3,518 total articles

Nvidia's $2 Billion Stake in CoreWeave Reinforces AI Infrastructure Push; Stifel Sticks with Hold

Nvidia's $2 Billion Stake in CoreWeave Reinforces AI Infrastructure Push; Stifel Sticks with Hold

Nvidia has invested $2.0 billion in CoreWeave at $87.20 per share, boosting its ownership to roughly 9.0%. Stifel retains a Hold rating on CoreWeave stock even as the company reports 235.4% revenue growth over the last year and trades at $98.31. The deal is expected to accelerate up to 200MW of capacity growth by 2030 within CoreWeave's 5GW AI Fact…

Scotiabank Starts Coverage of CGI With Sector Perform, C$140 Target

Scotiabank Starts Coverage of CGI With Sector Perform, C$140 Target

Scotiabank has initiated coverage of CGI Group Inc with a Sector Perform rating and a C$140.00 price objective. The bank cites the company’s exposure to discretionary IT spending in its Consulting business as the primary reason for a neutral stance, while noting valuation metrics that sit modestly above peer averages. CGI has also announced a globa…

JPMorgan Sticks With Overweight on Protagonist; Royalties and Upcoming Catalysts Drive Valuation Talk

JPMorgan Sticks With Overweight on Protagonist; Royalties and Upcoming Catalysts Drive Valuation Talk

JPMorgan has reaffirmed an Overweight rating on Protagonist Therapeutics (PTGX) and kept a $93.00 price target after a recent pullback in the stock. The firm points to royalty streams tied to Icotyde and rusfertide, an advancing oral IL-17 program and newly disclosed obesity initiatives as central to investor attention. Multiple analysts have also …

JPMorgan Sticks With Overweight on Vera Therapeutics, Sees Near-Term Upside as FDA Moves Atacicept Forward

JPMorgan Sticks With Overweight on Vera Therapeutics, Sees Near-Term Upside as FDA Moves Atacicept Forward

JPMorgan reiterated its Overweight rating and $96.00 price target on Vera Therapeutics (NASDAQ: VERA), signaling substantial upside from the stock's current trading level. The firm highlighted atacicept, Vera's lead candidate for immunoglobulin A nephropathy (IgAN), as well positioned in the B-Cell modulator space. The outlook is reinforced by an F…

Citizens Keeps Market Perform on Peloton Ahead of FY2Q26 Results

Citizens Keeps Market Perform on Peloton Ahead of FY2Q26 Results

Citizens reiterated a Market Perform rating on Peloton Interactive (PTON) ahead of the company’s FY2Q26 earnings release, citing disciplined expense management that could bolster EBITDA while remaining cautious on near-term subscriber growth after recent price increases. Analysts tracked by InvestingPro expect Peloton to return to profitability thi…

Citizens Keeps Market Perform on Alexandria Real Estate After Q4 Results, Flags Financing and Lease-Rollover Risks

Citizens Keeps Market Perform on Alexandria Real Estate After Q4 Results, Flags Financing and Lease-Rollover Risks

Citizens has reaffirmed a Market Perform rating on Alexandria Real Estate Equities (NYSE: ARE) following the REIT's fourth-quarter report. Alexandria reported Core FFO of $2.16 per share, marginally above both Citizens' and consensus expectations of $2.14, and management confirmed full-year 2026 guidance first disclosed in December 2025. The compan…

Evercore ISI Affirms Outperform on Texas Instruments, Sees 15% Upside

Evercore ISI Affirms Outperform on Texas Instruments, Sees 15% Upside

Evercore ISI has reaffirmed an Outperform rating on Texas Instruments with a $226 price target, implying roughly 15% upside from the current $196.59 share price. The research note cites investor underweighting in analog and microcontroller chips ahead of fourth-quarter earnings, the potential for data-center market share gains in 2026, and an upcom…